RevealDx
Summary active Updated Aug 6, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
About
RevealDx is a Seattle-based medical AI company that develops RevealAI-Lung, software that generates a Malignancy Similarity Index (mSI) score for lung nodules to help radiologists distinguish benign nodules from early-stage lung cancers 1. The mSI is derived from real-world reference data from the National Lung Screening Trial, stratifying risk across more than 1,500 patient cohorts 1. RevealAI-Lung holds FDA clearance, European MDR certification, and Australian TGA approval, and is covered under U.S. Medicare CPT codes 0721T and 0722T 1.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-08-05 | Strategic Investment | $3.4M | 4DMedical | — 12 |
The investment is paired with a global distribution agreement under which 4DMedical will embed RevealAI-Lung into its contextflow chest CT platform and pair it with 4DMedical’s CT:VQ ventilation-perfusion functional imaging software 12.
What Investors Say
No independently sourced investor quotes beyond press release boilerplate at time of profile creation.
What Founders Say
No independently sourced founder testimonials found at time of profile creation.
Sources
-
HIT Consultant, “4DMedical Invests $3.4M in RevealDx to Build a Connected Cardiopulmonary Platform,” August 5, 2026. Accessed August 2026. https://hitconsultant.net/2026/08/05/revealdx-secures-investment-4dmedical-distribution-revealai-lung/↩↩↩↩↩
-
4DMedical, “AI Lung Cancer Risk Assessment Meets Functional Lung Imaging Through New 4DMedical-RevealDx Partnership,” accessed August 2026. https://4dmedical.com/ai-lung-cancer-risk-assessment-functional-imaging/↩↩